Evidence of associations of APOBEC3B gene deletion with susceptibility to persistent HBV infection and hepatocellular carcinoma.

APOBEC3s are a family of cytidine deaminases involved in innate cellular immunity against virus including hepatitis B virus (HBV). A germline deletion across APOBEC3A and APOBEC3B (A3B) genes results in complete removal of the A3B coding region and destroys A3B expression. To determine whether this deletion affects susceptibility to HBV infection and HBV-related hepatocellular carcinoma (HCC), A3B genotypes were analyzed in 1124 individuals with HCC, 510 individuals with persistent HBV infection and 826 healthy controls and the association was estimated by odds ratio (OR) and 95% confidence interval (CI) computed by logistic regression. We also examined the effects of A3B on HBV genome hypermutation and replication in HCC cells. We observed a significantly higher frequency of the A3B deletion allele in persistent HBV carriers (33.3%; P = 0.0015) and HCC patients (37.9%; P = 1.28 × 10(-11)) compared with that in controls (27.5%). An increased risk for persistent HBV infection (OR = 1.35, 95% CI: 1.03-1.77) and HCC development (OR = 1.90, 95% CI: 1.58-2.28) was associated with at least one A3B deletion allele (+/- or -/- genotype) compared with the +/+ genotype. Transfection of A3B in HepG2 cells caused a substantial reduction of HBV RNA levels and G → A hypermutation in the HBV genome. Interestingly, a cytidine deaminase null mutant of A3B (E255A) also inhibited HBV RNA production although it was unable to edit HBV. These results suggest that the deletion of A3B attenuates HBV clearance, which in turn may result in persistent HBV infection and increased risk for developing HCC. Further studies are needed to verify our findings.

[1]  A. Børresen-Dale,et al.  Mutational Processes Molding the Genomes of 21 Breast Cancers , 2012, Cell.

[2]  Yusuke Nakamura,et al.  Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers , 2011, Nature Genetics.

[3]  V. Pathak,et al.  The Role of Amino-Terminal Sequences in Cellular Localization and Antiviral Activity of APOBEC3B , 2011, Journal of Virology.

[4]  Yusuke Nakamura,et al.  Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma , 2011, Nature Genetics.

[5]  Hsuan-Cheng Huang,et al.  Hepatitis B viraemia: its heritability and association with common genetic variation in the interferon γ signalling pathway , 2010, Gut.

[6]  Fuchu He,et al.  Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers , 2010, Nature Genetics.

[7]  Xing-Xing He,et al.  Persistent effect of IFNAR-1 genetic polymorphism on the long-term pathogenesis of chronic HBV infection. , 2010, Viral immunology.

[8]  V. Mazzaferro,et al.  Massive APOBEC3 Editing of Hepatitis B Viral DNA in Cirrhosis , 2010, PLoS pathogens.

[9]  A. Zaranek,et al.  A Survey of Genomic Traces Reveals a Common Sequencing Error, RNA Editing, and DNA Editing , 2010, PLoS genetics.

[10]  M. Karin,et al.  Immunity, Inflammation, and Cancer , 2010, Cell.

[11]  M. Stenglein,et al.  APOBEC3 proteins mediate the clearance of foreign DNA from human cells , 2010, Nature Structural &Molecular Biology.

[12]  Yusuke Nakamura,et al.  Effects of structural variations of APOBEC3A and APOBEC3B genes in chronic hepatitis B virus infection , 2009, Hepatology research : the official journal of the Japan Society of Hepatology.

[13]  J. Goedert,et al.  APOBEC3B deletion and risk of HIV-1 acquisition. , 2009, The Journal of infectious diseases.

[14]  Sharon J. Diskin,et al.  Copy number variation at 1q21.1 associated with neuroblastoma , 2009, Nature.

[15]  M. Weitzman,et al.  Deaminase-Independent Inhibition of Parvoviruses by the APOBEC3A Cytidine Deaminase , 2009, PLoS pathogens.

[16]  Y. Kamatani,et al.  A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians , 2009, Nature Genetics.

[17]  Pär Stattin,et al.  Association of a germ-line copy number variation at 2p24.3 and risk for aggressive prostate cancer. , 2009, Cancer research.

[18]  R. Stevens,et al.  Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications , 2008, Nature.

[19]  H. Blum,et al.  Hypermutation of hepatitis B virus genomes by APOBEC3G, APOBEC3C and APOBEC3H. , 2008, The Journal of general virology.

[20]  W. Greene,et al.  The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. , 2008, Annual review of immunology.

[21]  Shu Zheng,et al.  Association of human APOBEC3 cytidine deaminases with the generation of hepatitis virus B x antigen mutants and hepatocellular carcinoma , 2007, Hepatology.

[22]  M. Malim,et al.  Hepatitis B virus DNA is subject to extensive editing by the human deaminase APOBEC3C , 2007, Hepatology.

[23]  E. Eichler,et al.  Population Stratification of a Common APOBEC Gene Deletion Polymorphism , 2007, PLoS genetics.

[24]  J. Villeneuve,et al.  Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. , 2007, Journal of hepatology.

[25]  W. J. Esselman,et al.  Identification of APOBEC3DE as Another Antiretroviral Factor from the Human APOBEC Family , 2006, Journal of Virology.

[26]  J. Cheong,et al.  Association between chronic hepatitis B virus infection and interleukin‐10, tumor necrosis factor‐α gene promoter polymorphisms , 2006, Journal of gastroenterology and hepatology.

[27]  J. V. Moran,et al.  Cellular inhibitors of long interspersed element 1 and Alu retrotransposition. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[28]  S. Wain-Hobson,et al.  Interferon‐inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication , 2006, Hepatology.

[29]  S. Wahl,et al.  Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti–HIV-1 activity , 2006, The Journal of experimental medicine.

[30]  B. Cullen,et al.  APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells , 2006, Nucleic acids research.

[31]  M. Malim,et al.  APOBEC‐mediated interference with hepadnavirus production , 2005, Hepatology.

[32]  S. Wain-Hobson,et al.  Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[33]  M. Imamura,et al.  G to A hypermutation of hepatitis B virus , 2005, Hepatology.

[34]  R. König,et al.  APOBEC3B and APOBEC3C Are Potent Inhibitors of Simian Immunodeficiency Virus Replication* , 2004, Journal of Biological Chemistry.

[35]  D. Trono,et al.  Response to Comment on "Inhibition of Hepatitis B Virus Replication by APOBEC3G" , 2004, Science.

[36]  M. Malim,et al.  Cytidine Deamination of Retroviral DNA by Diverse APOBEC Proteins , 2004, Current Biology.

[37]  D. Ganem,et al.  Hepatitis B virus infection--natural history and clinical consequences. , 2004, The New England journal of medicine.

[38]  L. Barcellos,et al.  Gene copy number regulates the production of the human chemokine CCL3‐L1 , 2002, European journal of immunology.

[39]  Wen Tan,et al.  Copy number variation at 6q13 functions as a long-range regulator and is associated with pancreatic cancer risk. , 2012, Carcinogenesis.

[40]  H. El‐Serag,et al.  Hepatocellular carcinoma. , 2011, The New England journal of medicine.

[41]  Tara L. Kieffer,et al.  Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis , 2009 .

[42]  B. Koblin,et al.  Hepatitis B virus infection. , 1998, The New England journal of medicine.

[43]  F. Chisari,et al.  Hepatitis B virus immunopathogenesis. , 1995, Annual review of immunology.